This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
per cent, and 3 per cent, respectively, between 2022 and 2028. In recent years, key China-based companies like RemeGen, Jiangsu-Hengrui Medicine , and Zhejiang Medicine/NovoCodex have ventured into the ADC-based treatment space through active research and development. per cent, 1.6
By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. There are a total of 124 companies involved in CAR-T cell drugdevelopment for this indication.
Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. Faslodex will be administered in the control arm of the Phase III study, allowing for direct comparison between the two ER degraders.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
2028 
98 
Let's personalize your content